Noxopharm Limited (ASX:NOX)

Market Cap	21.51M -13.4%
Revenue (ttm)	3.40M +44.8%
Net Income	-5.49M
EPS	-0.02
Shares Out	307.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,644
Average Volume	147,902
Open	0.0700
Previous Close	0.0720
Day's Range	0.0700 - 0.0700
52-Week Range	0.0430 - 0.1350
Beta	0.03
RSI	50.62
Earnings Date	Jun 3, 2026

About Noxopharm

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NOX

Financial Performance

In fiscal year 2025, Noxopharm's revenue was 2.82 million, an increase of 17.52% compared to the previous year's 2.40 million. Losses were -4.88 million, 36.5% more than in 2024.